Infliximab before colectomy in refractory IBDU

What is known

• In a cohort of 20 patients with severe refractory indeterminate colitis, 70% had a complete response to infliximab and the 4 non-responders underwent colectomy with IPAA. ¹
• Half the patients were reclassified as Crohn's disease during follow-up; infliximab efficacy was similar in reclassified and still-indeterminate patients. ¹
• Indeterminate colitis patients have more pelvic sepsis, pouch fistula, and pouch failure after IPAA than ulcerative colitis patients, making pre-surgical diagnostic clarification relevant. ^1,2

What is unknown / caveats

• Evidence rests on a single small (n=20) retrospective cohort
• No controlled comparison of surgery-first versus infliximab-then-surgery
• Whether infliximab exposure before colectomy affects postoperative surgical morbidity is not resolved in the provided excerpts.

References

1. Papadakis KA, Treyzon L, Abreu MT, Fleshner PR, Targan SR, Vasiliauskas EA. Infliximab in the treatment of medically refractory indeterminate colitis. Aliment Pharmacol Ther. 2003;18(7):741-7. PMID: 14510748.

2. Tremaine WJ. Is indeterminate colitis determinable?. Curr Gastroenterol Rep. 2012;14(2):162-5. PMID: 22314810.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct.